FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326005988> ?p ?o ?g. }

• W2326005988 endingPage "2" @default.
• W2326005988 startingPage "1" @default.
• W2326005988 abstract "OBJECTIVE:We had done our study to measure the efficacy of iron sucrose in iron deficiency anemia in antenatal patients. METHOD :In our prospective study 50 patients were included.all of them were having usg maturity between 15-34 weeks. All of them were given iron sucrose i.v. according to their requirements.and follow-up was taken after 4 weeks by measuring Hb level. RESULT:Hb level improved significantly (2.1 gms)within a short duration of interval.very few(12%) patients suffered from minor side effects. CONCLUSION:Iron sucrose has been found very useful for correction of iron deficiency anemia in antenatal patients. INTRODUCTION:Anemia is estimated to affect nearly two thirds of the pregnant women in developing countries . Iron deficiency anemia is responsible for 95% of the anemias during pregnancy . The responsible constellation of factors producing IDA generally precedes the pregnancy, including diet poor in iron content coupled with menstrual losses and a rapid succession of pregnancies in which supplemental iron was not provided. Most women begin their pregnancy with partially or completely depleted iron reserves. Thus,the severity of the anemia is inversely related to the amount of iron reserves . During pregnancy, there is a great demand for iron to meet the requirement of red blood cell mass expansion in the mother, fetal and placental blood and blood loss at delivery . In pregnancy, iron deficiency is exaggerated because of the ability of fetus to extract its requirement in obligatory one way direction even from iron deficient mothers .This is aggravated by poor absorption of iron due to adverse effects of pregnancy on the gastrointestinal tract, which include nausea and vomiting, motility disorder with reflux esophagitis and indigestion . In underdeveloped countries, anemia is a major contributory factor to maternal morbidity and mortality . Inadequate antenatal care along with poor knowledge of dietary needs of pregnant woman, and overall poor socio-economic conditions are all responsible for this in our country . Other countries of the Asian region like Indonesia and India also report high prevalence of IDA in pregnancy and associated maternal and fetal loss. It is also associated with high perinatal mortality rate in our region . A recent study reported a fetal mortality rate of 50% at 5 month, 28% at 7 months and 24% at 9months of gestation . Over the past years, various oral, intramuscular and intravenous preparations of iron have been used for correction of IDA in the pregnant patients . However, they are associated with significant side effects and it is not possible to achieve the target rise in Hb level in a limited time-period when patient is approaching the term. Iron sucrose4complex (ISC) is a relatively new drug, which is used intravenously for the correction of IDA . The drug has been able to raise the Hb to satisfactory level when used in severely anemic iron deficient pregnant women . The aim of this study was to assess the efficacy and tolerability of ISC in pregnant patients with IDA seen at our institution. What is iron sucrose injection? Iron sucrose is a form of the mineral iron. Iron is important for many functions in the body, especially for the transport of oxygen in the blood. Iron sucrose injection is used to treat iron deficiency anemia in people with kidney disease. It is usually given with another medication to promote the growth of red blood .This medication is not for treating other forms of anemia not caused by iron deficiency. Pharmacokinetics:Half-life elimination: 6 hr Vd: 7.9-10 L Clearance: 1.2 L/hr Excretion: Urine (5%) METHOD:we had done our study in V.S.HOSPITAL, A’BAD,during march to august 2013 .it was a prospective study.we had included 50 patients in our study who were suffering from iron deficiency anemia(Hb 6-8 gm%).they all were given iron sucrose infusion according to their requirment. REQUIRMENT OF IRON=2.3{[12-pt’s Hb]wt}+500 gms. iron sucrose infusion was given on alternate day.a single dose consist of 200 mg iron sucrose in 100 ml normal saline. EXCLUSION CRITERIA (1)pt having allergic reaction to iron sucrose (2)pt having usg maturity 34weeks (3)pt having Hb 8 gm (4)anemia resulting from other causes follow up was taken after 4 weeks , by measuring Hb level." @default.
• W2326005988 created "2016-06-24" @default.
• W2326005988 creator A5023936984 @default.
• W2326005988 creator A5060781781 @default.
• W2326005988 creator A5063081197 @default.
• W2326005988 date "2011-10-01" @default.
• W2326005988 modified "2023-09-24" @default.
• W2326005988 title "Effect of Iron Sucrose Infusion in Iron Deficiency Anemia During Pregnancy" @default.
• W2326005988 doi "https://doi.org/10.15373/2249555x/oct2013/108" @default.
• W2326005988 hasPublicationYear "2011" @default.
• W2326005988 type Work @default.
• W2326005988 sameAs 2326005988 @default.
• W2326005988 citedByCount "0" @default.
• W2326005988 crossrefType "journal-article" @default.
• W2326005988 hasAuthorship W2326005988A5023936984 @default.
• W2326005988 hasAuthorship W2326005988A5060781781 @default.
• W2326005988 hasAuthorship W2326005988A5063081197 @default.
• W2326005988 hasBestOaLocation W23260059881 @default.
• W2326005988 hasConcept C126322002 @default.
• W2326005988 hasConcept C131872663 @default.
• W2326005988 hasConcept C185592680 @default.
• W2326005988 hasConcept C2776732101 @default.
• W2326005988 hasConcept C2776974161 @default.
• W2326005988 hasConcept C2777417653 @default.
• W2326005988 hasConcept C2778248108 @default.
• W2326005988 hasConcept C2778597767 @default.
• W2326005988 hasConcept C2779234561 @default.
• W2326005988 hasConcept C2780084898 @default.
• W2326005988 hasConcept C3020614022 @default.
• W2326005988 hasConcept C31903555 @default.
• W2326005988 hasConcept C54355233 @default.
• W2326005988 hasConcept C71924100 @default.
• W2326005988 hasConcept C86803240 @default.
• W2326005988 hasConceptScore W2326005988C126322002 @default.
• W2326005988 hasConceptScore W2326005988C131872663 @default.
• W2326005988 hasConceptScore W2326005988C185592680 @default.
• W2326005988 hasConceptScore W2326005988C2776732101 @default.
• W2326005988 hasConceptScore W2326005988C2776974161 @default.
• W2326005988 hasConceptScore W2326005988C2777417653 @default.
• W2326005988 hasConceptScore W2326005988C2778248108 @default.
• W2326005988 hasConceptScore W2326005988C2778597767 @default.
• W2326005988 hasConceptScore W2326005988C2779234561 @default.
• W2326005988 hasConceptScore W2326005988C2780084898 @default.
• W2326005988 hasConceptScore W2326005988C3020614022 @default.
• W2326005988 hasConceptScore W2326005988C31903555 @default.
• W2326005988 hasConceptScore W2326005988C54355233 @default.
• W2326005988 hasConceptScore W2326005988C71924100 @default.
• W2326005988 hasConceptScore W2326005988C86803240 @default.
• W2326005988 hasIssue "10" @default.
• W2326005988 hasLocation W23260059881 @default.
• W2326005988 hasOpenAccess W2326005988 @default.
• W2326005988 hasPrimaryLocation W23260059881 @default.
• W2326005988 hasRelatedWork W1588537959 @default.
• W2326005988 hasRelatedWork W2105002681 @default.
• W2326005988 hasRelatedWork W2109305563 @default.
• W2326005988 hasRelatedWork W2138227677 @default.
• W2326005988 hasRelatedWork W2163485286 @default.
• W2326005988 hasRelatedWork W3085626966 @default.
• W2326005988 hasRelatedWork W3211870447 @default.
• W2326005988 hasRelatedWork W4322012644 @default.
• W2326005988 hasRelatedWork W2181556225 @default.
• W2326005988 hasRelatedWork W2186385703 @default.
• W2326005988 hasVolume "3" @default.
• W2326005988 isParatext "false" @default.
• W2326005988 isRetracted "false" @default.
• W2326005988 magId "2326005988" @default.
• W2326005988 workType "article" @default.